A/Prof Vilija Jokubaitis
banner
vjokubaitis.bsky.social
A/Prof Vilija Jokubaitis
@vjokubaitis.bsky.social
Clinical and translational Neuroimmunologist working in Multiple Sclerosis prognostics, genomics and women’s health.
Pinned
🚨 Calling Australian women with #MultipleSclerosis to take part in the MS Australian women’s midlife years (MS-AMY) study. We want to understand your physical, psychological, sexual and socioeconomic wellbeing, and how #menopause impacts this.

More information below:
www.monash.edu/medicine/tra...
The Multiple Sclerosis Australian Women’s Midlife Years (MS-AMY) study
www.monash.edu
Reposted by A/Prof Vilija Jokubaitis
Today we had our first early-mid career researcher learning development session presented by Prof Amy Brodtmann @monashuniversity.bsky.social about how to get your paper published. Key take away - Make your science clear, convoluted and complex does NOT equal clever! #scicomm #EMCR #academia
October 27, 2025 at 3:15 AM
Today, our study looking at the impact of menopause on #MultipleSclerosis disease progression was published in @jamaneurology.com We show that in 987 women with relapsing disease, menopause does not increase the risk of progression. Rather somatic aging is the primary driver of disability in midlife
In this study, menopause was not the primary driver of multiple sclerosis clinical progression in women at midlife.

ja.ma/4mD3GoK
September 29, 2025 at 11:34 PM
Amazing work by my PhD student Dr Jessica Shipley is out exploring the impacts of pregnancy on relapse and disability outcomes in women woth moderate to severe disability. We found that like in women with mild disease, relapse rates fell by up to 75% in this population.
Pregnancy in women with moderate to severe MS reduced relapse rates by 59% to 75% during pregnancy, increased them by 36% postpartum, but did not influence long-term disability progression compared to nonpregnant women. ja.ma/4n7jO2V
September 16, 2025 at 12:46 AM
🚨 Calling Australian women with #MultipleSclerosis to take part in the MS Australian women’s midlife years (MS-AMY) study. We want to understand your physical, psychological, sexual and socioeconomic wellbeing, and how #menopause impacts this.

More information below:
www.monash.edu/medicine/tra...
The Multiple Sclerosis Australian Women’s Midlife Years (MS-AMY) study
www.monash.edu
July 28, 2025 at 1:57 AM
Thanks for a great chat this morning @drshanerrr.bsky.social! In anticipation of the day of immunology on Tuesday 29th April and the public lecture at the Doherty Institute, we got to chat all things #MultipleSclerosis and #Immunology

www.rrr.org.au/explore/prog...
April 20, 2025 at 4:54 AM
Excited to be speaking at the Australia and New Zealand Day of Immunology Public Lecture on 29 April, 6pm at the Doherty Institute, Melbourne. I’ll be joining colleagues to explore the world of #neuroimmunology —where the brain meets the immune system. Free event, open to all! Register below👇
April 17, 2025 at 7:29 AM
Gearing up to speak about all things #pregnancy and #MultipleSclerosis at the #AAN conference in San Diego tomorrow. Tag teaming with the amazing #RileyBove and #KerstinHellwig
April 5, 2025 at 4:11 AM
We found that PIRA was a rare event in #NMOSD with most disability occurring as a result of relapse activity. This means that the clinical priority should remain relapse prevention in this condition.
December 17, 2024 at 7:08 AM
Sex and sex hormones influence #MultipleSclerosis outcomes through effects on both the immune and nervous systems. In our perspective published today in @natureportfolio.bsky.social we explore the role of sex hormones and gender diversity in MS. Our article can be found here 👉🏻 rdcu.be/d23Hp
Exploring the role of sex hormones and gender diversity in multiple sclerosis
Nature Reviews Neurology - Evidence for the effects of sex hormones on inflammation, myelination and neurodegeneration has implications for both cisgender and gender-diverse individuals with...
rdcu.be
December 11, 2024 at 1:55 AM
Jokubaitis Lab Christmas party. So grateful to work with this incredible group of people. Reflecting on 2024, we’ve published 17 papers across MS and pregnancy, menopause, cancer risk, biomarkers and treatment efficacy, with another 6 under review, and 9 in preparation. What a hard working team! 🤩
December 8, 2024 at 7:00 AM
Reposted by A/Prof Vilija Jokubaitis
Our Alfred Health MS and Neuroimmunology end of year Mystery Surprise Party! Sharing a special recipe, book exchange or awesome home made bracelets- it’s all part of the fun. So grateful for this amazing team!! @vjokubaitis.bsky.social @monashuniversity.bsky.social
December 4, 2024 at 2:47 AM
As more people live longer with multiple sclerosis thanks to advances in #MS disease modifying therapies, our recent review published in the Multiple Sclerosis Journal explores navigating a dual diagnosis of MS and cancer. journals.sagepub.com/doi/10.1177/...
Multiple sclerosis and cancer: Navigating a dual diagnosis - Cassie Nesbitt, Anneke Van Der Walt, Helmut Butzkueven, Bianca Devitt, Vilija G Jokubaitis, 2024
Healthcare breakthroughs are extending the lives of multiple sclerosis (MS) patients and cancer survivors, creating a growing cohort of individuals navigating a...
journals.sagepub.com
November 25, 2024 at 10:08 AM
Slowly transitioning to this new platform. So great to see many colleagues here already 😀
Stay tuned for #multiplesclerosis and #womenshealth related posts and possibly other random bits and pieces
November 18, 2024 at 3:58 AM